COMPANY

Aminex Therapeutics

Keywords: oncology small molecule cancer HER2-low Hormone Receptor Positive Breast Cancer DIPG Brain Tumor Ovary Cancer Breast Cancer Papillary Thyroid Cancer Head and Neck Cancer Gastric Cancer Nsclc Mesotheliomas Pleural Mesothelioma Peritoneum Esophageal Cancer H3 K27M-Mutant Diffuse Midline Glioma Endometrial Cancer Cervical Cancer Melanoma Colorectal Cancer Malignant Glioma Medication Toxicity Tolerance AMXT1501 AMXT 1501 Dicaprate AMXT 1501

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Form D reports $15.08M sold since 2022 (filed Dec 5, 2025). SEC Form D 0001470831-25-000383 (Dec 5, 2025)
Evidence (1 event)
- Dec 5, 2025 · SEC Form D 0001470831-25-000383
  Name of Issuer: Aminex Therapeutics, Inc.; CIK: 1613386; Address: Kenmore, WA; Submission type: D; Filing date: 2025-12-05; Industry Group: Biotechnology; Date of First Sale: 2022-10-25; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 30000030; Total Amount Sold: 15084670; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jan 26, 2026 Trial start Phase 1/Phase 2: Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors source ↗
Nov 29, 2022 Trial start Phase 1/Phase 2: Oral AMXT 1501 Dicaprate in Combination With IV DFMO source ↗
Jun 12, 2018 Trial start Phase 1: Oral AMXT 1501 Dicaprate in Combination With DFMO source ↗
Jun 12, 2018 Trial start Phase 1: Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers source ↗

Upcoming milestones

Feb 28, 2028 (ESTIMATED) · Phase 1/Phase 2 · Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors · NCT07287917

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT07287917	Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors	Phase 1/Phase 2	Recruiting	Jan 26, 2026	Feb 28, 2028 (estimated)
NCT05500508	Oral AMXT 1501 Dicaprate in Combination With IV DFMO	Phase 1/Phase 2	Terminated	Nov 29, 2022	Dec 12, 2024 (actual)
NCT03536728	Oral AMXT 1501 Dicaprate in Combination With DFMO	Phase 1	Completed	Jun 12, 2018	Dec 30, 2022 (actual)
NCT03077477	Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers	Phase 1	Withdrawn	Jun 12, 2018	Jun 12, 2018 (actual)